This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Treatment of Obesity With Vitamin D (40.000 IE Per Week for 1 Year)

This study has been completed.
Information provided by:
University of Tromso Identifier:
First received: October 20, 2005
Last updated: May 8, 2008
Last verified: May 2008
The purpose of the study is to evaluate if supplementation with vitamin D in doses of 20.000IU per week and 40.000 IU per week will result in weight loss in obese subjects as compared to placebo during 1 year.

Condition Intervention Phase
Obesity Drug: Cholecalciferol Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment

Resource links provided by NLM:

Further study details as provided by University of Tromso:

Primary Outcome Measures:
  • Body Weight
  • Body composition
  • Measures of calcium metabolism
  • Insulin sensitivity
  • Muscle strength
  • Depression score
  • Blood pressure

Estimated Enrollment: 450
Study Start Date: November 2005
Study Completion Date: December 2007
Detailed Description:
We will include 450 obese subjects that will be devided in 3 groups: 40.000IU cholecalciferol per week, 20.000 IU cholecalciferol per week, and placebo. All subjects will be given 500 mg calcium per day. There will be visits every tird month. In addition to weight reduction, we will also evaluate the calcium metabolism (blood test and urin samples), insulin sensitivity, muscle strenght, blood pressure and depression.

Ages Eligible for Study:   21 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • BMI 30 - 40
  • serum calcium < 2.55 mmol/L

Exclusion Criteria:

  • serious diseases
  • reduced kidney function
  • renal stone disease
  • using psychopharmaca
  • using drugs for weight reduction
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00243256

Clinical Research Unit, University Hospital of North Norway
Tromsø, Norway, 9038
Sponsors and Collaborators
University of Tromso
Principal Investigator: Rolf Jorde, Professor University of Tromsø, Tromsø, Norway
  More Information

Publications automatically indexed to this study by Identifier (NCT Number): Identifier: NCT00243256     History of Changes
Other Study ID Numbers: CSEMDT-2005-2
Study First Received: October 20, 2005
Last Updated: May 8, 2008

Additional relevant MeSH terms:
Nutrition Disorders
Body Weight
Signs and Symptoms
Growth Substances
Physiological Effects of Drugs
Bone Density Conservation Agents processed this record on September 21, 2017